Study summary · research use only
Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This human patient-survey study evaluated afamelanotide, an α-melanocyte-stimulating hormone analogue approved in the United States in 2019 for erythropoietic protoporphyria (EPP), using questionnaires on return to normal activities, phototoxic reactions, and patient confidence, among other outcomes, rated on a scale from 'very much' to 'never.' Before treatment, 75% of patients reported that EPP affected their lives 'very much' or 'a lot'; this fell to 11% after the 1st implant and to 0% after each subsequent implant. The number of patients who willingly went outside increased with each subsequent implant. The authors report that afamelanotide treatment was associated with changes in patients' reported quality of life in this survey.
Abstract
Erythropoietic protoporphyria (EPP) is a rare disease that causes disabling cutaneous photosensitivity with pain and burning sensations. In 2019, afamelanotide, an α-melanocyte-stimulating hormone analogue, was approved in the United States for treatment of EPP. In this study, patients receiving afamelanotide filled out questionnaires assessing the benefit of treatment. Outcomes measured included: return to normal activities, experience of phototoxic reactions, effect on patient confidence, and more. Patients ranked their experience on a descriptive scale ranging from "very much" to "never". Prior to treatment, 75% of patients indicated that EPP affected their lives "very much" or "a lot". This number fell to 11% after the 1st implant and to 0% after each subsequent implant. The number of patients that willingly ventured outside increased with each subsequent implant. The results of this study clearly show that afamelanotide treatment can dramatically and positively impact the lives of EPP patients. Citation: Resnik SR, Targett D, Resnik BI. Into the light: afamelanotide and the treatment of erythropoietic protoporphyria in the United States. J Drugs Dermatol. 2023;22(9):941-949. doi:10.36849/JDD.7126R1.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.